{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T14:57:04Z","timestamp":1791212224122,"version":"4.1.0"},"reference-count":79,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,10,1]],"date-time":"2016-10-01T00:00:00Z","timestamp":1475280000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cytokine"],"published-print":{"date-parts":[[2016,10]]},"DOI":"10.1016\/j.cyto.2016.07.015","type":"journal-article","created":{"date-parts":[[2016,8,4]],"date-time":"2016-08-04T03:45:34Z","timestamp":1470282334000},"page":"92-99","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":48,"special_numbering":"C","title":["Anti cytokine therapy in chronic inflammatory arthritis"],"prefix":"10.1016","volume":"86","author":[{"given":"Charlotte","family":"Thompson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruth","family":"Davies","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ernest","family":"Choy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cyto.2016.07.015_b0005","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.1056\/NEJMra1004965","article-title":"The pathogenesis of rheumatoid arthritis","volume":"365","author":"McInnes","year":"2011","journal-title":"N Engl. J. Med."},{"key":"10.1016\/j.cyto.2016.07.015_b0010","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1161\/01.CIR.0000054612.26458.B2","article-title":"Cardiovascular morbidity and mortality in women diagnosed with rheumatoid arthritis","volume":"107","author":"Solomon","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.cyto.2016.07.015_b0015","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1111\/j.1365-2796.2010.02260.x","article-title":"Rapid increase in myocardial infarction risk following diagnosis of rheumatoid arthritis amongst patients diagnosed between 1995 and 2006","volume":"268","author":"Holmqvist","year":"2010","journal-title":"J. Intern. Med."},{"key":"10.1016\/j.cyto.2016.07.015_b0020","doi-asserted-by":"crossref","first-page":"2665","DOI":"10.1002\/art.21972","article-title":"Classification criteria for psoriatic arthritis: development of new criteria from a large international study","volume":"54","author":"Taylor","year":"2006","journal-title":"Arthritis. Rheum."},{"key":"10.1016\/j.cyto.2016.07.015_b0025","first-page":"449","article-title":"Interleukin-1 and tumor necrosis factor mRNA expression in rheumatoid arthritis: prolonged production of IL-1\u03b1","volume":"73","author":"Buchan","year":"1988","journal-title":"Clin. Exp. Immunol."},{"issue":"5","key":"10.1016\/j.cyto.2016.07.015_b0030","doi-asserted-by":"crossref","first-page":"R136","DOI":"10.1186\/ar4317","article-title":"Th17 and Th22 cells in psoriatic arthritis and psoriasis","volume":"15","author":"Benham","year":"2013","journal-title":"Arthritis. Res. Ther."},{"issue":"6","key":"10.1016\/j.cyto.2016.07.015_b0035","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/j.jbspin.2011.05.023","article-title":"Biologic agents for treating ankylosing spondylitis: beyond TNF\u03b1 antagonists","volume":"78","author":"Wendling","year":"2011","journal-title":"Joint Bone Spine"},{"issue":"3","key":"10.1016\/j.cyto.2016.07.015_b0040","doi-asserted-by":"crossref","first-page":"R95","DOI":"10.1186\/ar3370","article-title":"Analysis of IL-17(+) cells in facet joints of patients with spondyloarthritis suggests that the innate immune pathway might be of greater relevance than the Th17-mediated adaptive immune response","volume":"13","author":"Appel","year":"2011","journal-title":"Arthritis. Res. Ther."},{"issue":"6","key":"10.1016\/j.cyto.2016.07.015_b0045","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1002\/art.37937","article-title":"In situ analysis of interleukin-23- and interleukin-12-positive cells in the spine of patients with ankylosing spondylitis","volume":"65","author":"Appel","year":"2013","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.cyto.2016.07.015_b0050","first-page":"1","article-title":"What is the evidence for the presence of a therapeutic window of opportunity in rheumatoid arthritis? A systematic literature review","author":"van Nies","year":"2013","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.cyto.2016.07.015_b0055","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1093\/rheumatology\/keh199","article-title":"Benefit of very early referral and very early therapy with disease-modifying anti-rheumatic drugs in patients with early rheumatoid arthritis","volume":"43","author":"Nell","year":"2004","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.cyto.2016.07.015_b0060","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1136\/annrheumdis-2011-201066","article-title":"Combination etanercept and methotrexate provides better disease control in very early (\u2a7d4 months) versus early rheumatoid arthritis (>4 months and <2 years): post hoc analyses from the COMET study","volume":"71","author":"Emery","year":"2012","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.cyto.2016.07.015_b0065","doi-asserted-by":"crossref","first-page":"1939","DOI":"10.1002\/art.20253","article-title":"Efficacy and safety of leflunomide in the treatment of psoriatic arthritis and psoriasis: a multinational, double-blind, randomized, placebo-controlled clinical trial","volume":"50","author":"Kaltwasser","year":"2004","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.cyto.2016.07.015_b0070","first-page":"CD000212","article-title":"Interventions for psoriatic arthritis","volume":"3","author":"Jones","year":"2000","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.cyto.2016.07.015_b0075","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1056\/NEJMoa0810652","article-title":"Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis","volume":"362","author":"Griffiths","year":"2010","journal-title":"N Engl. J. Med."},{"issue":"10","key":"10.1016\/j.cyto.2016.07.015_b0080","doi-asserted-by":"crossref","first-page":"2645","DOI":"10.1002\/art.38070","article-title":"The impact of TNF-inhibitors on radiographic progression in ankylosing spondylitis","volume":"65","author":"Haroon","year":"2013","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.cyto.2016.07.015_b0085","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1093\/rheumatology\/kes001","article-title":"A randomized placebo-controlled trial of MTX in psoriatic arthiritis","volume":"51","author":"Kingsley","year":"2012","journal-title":"Rheumatology"},{"issue":"8657","key":"10.1016\/j.cyto.2016.07.015_b0090","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/S0140-6736(89)90430-3","article-title":"Inhibitory effect of TNF alpha antibodies on synovial cell interleukin-1 production in rheumatoid arthritis","volume":"292","author":"Brennan","year":"1989","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.cyto.2016.07.015_b0095","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1002\/art.1780390702","article-title":"Decrease in cellularity and expression of adhesion molecules by anti-tumor necrosis factor alpha monoclonal antibody treatment in patients with rheumatoid arthritis","volume":"39","author":"Tak","year":"1996","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.cyto.2016.07.015_b0100","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1002\/art.1780380511","article-title":"Dysregulation of the in vivo production of interleukin-1 receptor antagonist in patients with rheumatoid arthritis","volume":"5","author":"Chikanza","year":"1995","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.cyto.2016.07.015_b0105","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1155\/2012\/539683","article-title":"The Th17\/IL-23 axis and natural immunity in psoriatic arthritis","volume":"2012","author":"Maeda","year":"2012","journal-title":"Int. J. Rheumatol."},{"issue":"4","key":"10.1016\/j.cyto.2016.07.015_b0110","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1517\/13543784.2012.669372","article-title":"Current investigational drugs in psoriasis","volume":"21","author":"Ryan","year":"2012","journal-title":"Exp. Opin. Investig. Drugs"},{"issue":"1","key":"10.1016\/j.cyto.2016.07.015_b0115","article-title":"Expression levels of interleukin-17A, interleukin-17F and their receptors in synovium of patients with rheumatoid arthritis, psoriatic arthritis and osteoarthritis: a target validation study","volume":"71","author":"van Baarsen","year":"2012","journal-title":"Arthritis Rheum."},{"issue":"12","key":"10.1016\/j.cyto.2016.07.015_b0120","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1136\/ard.2005.050963","article-title":"Detailed analysis of the cell infiltrate and the expression of mediators of synovial inflammation and joint destruction in the synovium of patients with psoriatic arthritis: implications for treatment","volume":"65","author":"van Kuijk","year":"2006","journal-title":"Ann. Rheum. Dis."},{"issue":"5","key":"10.1016\/j.cyto.2016.07.015_b0125","doi-asserted-by":"crossref","DOI":"10.1186\/ar2297","article-title":"IL-23 induces human osteoclastogenesis via IL-17 in vitro, and anti-IL-23 antibody attenuates collagen-induced arthritis in rats","volume":"9","author":"Yago","year":"2007","journal-title":"Arthritis Res. Ther."},{"issue":"5","key":"10.1016\/j.cyto.2016.07.015_b0130","doi-asserted-by":"crossref","first-page":"R136","DOI":"10.1186\/ar4317","article-title":"Th17 and Th22 cells in psoriatic arthritis and psoriasis","volume":"15","author":"Benham","year":"2013","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.cyto.2016.07.015_b0135","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1093\/bfgp\/elr023","article-title":"Progress in the genetics of ankylosing spondylitis","volume":"10","author":"Brown","year":"2011","journal-title":"Brief Funct. Genomics"},{"key":"10.1016\/j.cyto.2016.07.015_b0140","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1056\/NEJM197304052881403","article-title":"High association of an HLA antigen, W27, with ankylosing spondylitis","volume":"288","author":"Schlosstein","year":"1973","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.cyto.2016.07.015_b0145","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1038\/nrrheum.2012.41","article-title":"Reveille, genetics of spondyloarthritis\u2014beyond the MHC","volume":"8","author":"John","year":"2012","journal-title":"Nat. Rev. Rheumatol."},{"issue":"Suppl 3","key":"10.1016\/j.cyto.2016.07.015_b0150","first-page":"104","article-title":"In situ analysis of IL-23 secreting cells in the spine of patients with ankylosing spondylitis","volume":"69","author":"Appel","year":"2010","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.cyto.2016.07.015_b0155","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1002\/art.1780380407","article-title":"Use of immunohistologic and in situ hybridization techniques in the examination of sacroiliac joint biopsy specimens from patients with ankylosing spondylitis","volume":"38","author":"Braun","year":"1995","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.cyto.2016.07.015_b0160","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1016\/S0140-6736(02)08215-6","article-title":"Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial","volume":"6","author":"Braun","year":"2002","journal-title":"The Lancet"},{"issue":"4","key":"10.1016\/j.cyto.2016.07.015_b0165","doi-asserted-by":"crossref","first-page":"R127","DOI":"10.1186\/ar2794","article-title":"Canadian (M03\u2013606) study group. ATLAS study group. Assessment of radiographic progression in the spines of patients with ankylosing spondylitis treated with adalimumab for up to 2 years","volume":"11","author":"van der Heijde","year":"2009","journal-title":"Arthritis Res. Ther."},{"issue":"10","key":"10.1016\/j.cyto.2016.07.015_b0170","doi-asserted-by":"crossref","first-page":"2645","DOI":"10.1002\/art.38070","article-title":"The Impact of TNF-inhibitors on radiographic progression in Ankylosing Spondylitis","volume":"65","author":"Haroon","year":"2013","journal-title":"Arthritis Rheum."},{"issue":"1","key":"10.1016\/j.cyto.2016.07.015_b0175","doi-asserted-by":"crossref","first-page":"250","DOI":"10.3892\/etm.2014.2046","article-title":"T lymphocyte subset imbalances in patients contribute to ankylosing spondylitis","volume":"9","author":"Wang","year":"2015","journal-title":"Exp. Ther. Med."},{"key":"10.1016\/j.cyto.2016.07.015_b0180","unstructured":"Derek L. Mattey, Jonathan C. Packham, Nicola B. Nixon, Lucy Coates, Paul Creamer, Sarah Hailwood, Gordon J. Taylor, Ashok K. Bhalla, Association of cytokine and matrix metalloproteinase profiles with disease activity and function in ankylosing spondylitis."},{"key":"10.1016\/j.cyto.2016.07.015_b0185","doi-asserted-by":"crossref","unstructured":"C.H. Smith, A.V. Anstey, J.N.W.N. Barker, A.D. Burden,_ R.J.G. Chalmers, D.A. Chandler, A.Y. Finlay, C.E.M. Griffiths, K. Jackson, N.J. McHugh, K.E. McKenna, N.J. Reynolds and A.D. Ormerod, British Association of Dermatologists guidelines for biologic interventions for psoriasis 2009.","DOI":"10.1111\/j.1365-2133.2009.09505.x"},{"key":"10.1016\/j.cyto.2016.07.015_b0190","doi-asserted-by":"crossref","DOI":"10.1093\/rheumatology\/ket266","article-title":"Impact of biologic therapy on functional status in patients with rheumatoid arthritis: a meta-analysis","author":"Callhoff","year":"2013","journal-title":"Rheumatology"},{"key":"10.1016\/j.cyto.2016.07.015_b0195","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD005121.pub3","article-title":"Anakinra for rheumatoid arthritis","author":"Mertens","year":"2009","journal-title":"Cochrane Database Syst. Rev."},{"issue":"5","key":"10.1016\/j.cyto.2016.07.015_b0200","doi-asserted-by":"crossref","first-page":"609","DOI":"10.2165\/00003495-200969050-00007","article-title":"Tocilizumab: a review of its use in the management of rheumatoid arthritis","volume":"69","author":"Oldfield","year":"2009","journal-title":"Drugs"},{"key":"10.1016\/j.cyto.2016.07.015_b0205","unstructured":"June 12, 2014 Sanofi and Regeneron Announce New, Detailed Data from Positive Sarilumab Phase 3 Rheumatoid Arthritis Trial at EULAR. <http:\/\/investor.regeneron.com\/releasedetail.cfm?releaseid=854328>."},{"key":"10.1016\/j.cyto.2016.07.015_b0210","doi-asserted-by":"crossref","unstructured":"Mark C. Genovese, Roy Fleischmann, Daniel Furst, Namieta Janssen, John Carter, Bhaskar Dasgupta, Judy Bryson, Benjamin Duncan, Wei Zhu, Costantino Pitzalis, Patrick Durez, Kosmas Kretsos, Clinical and epidemiological research: Efficacy and safety of olokizumab in patients with rheumatoid arthritis with an inadequate response to TNF inhibitor therapy: outcomes of a randomised Phase IIb study. Ann Rheum Dis, <http:\/\/dx.doi.org\/10.1136\/annrheumdis-2013-204760>.","DOI":"10.1136\/annrheumdis-2013-204760"},{"key":"10.1016\/j.cyto.2016.07.015_b0215","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1136\/annrheumdis-2013-205137","article-title":"Sirukumab, a human anti-interleukin-6 monoclonal antibody: a randomised, 2-part (proof-of-concept and dose-finding), phase II study in patients with active rheumatoid arthritis despite methotrexate therapy","volume":"73","author":"Smolen","year":"2014","journal-title":"Ann. Rheum. Dis."},{"issue":"10 Suppl","key":"10.1016\/j.cyto.2016.07.015_b0220","first-page":"S735","article-title":"A Phase IIb study of the efficacy and safety of subcutaneous clazakizumab (anti-IL-6 monoclonal antibody) with or without methotrexate in adults with moderate-to-severe active rheumatoid arthritis and an inadequate response to methotrexate","volume":"65","author":"Weinblatt","year":"2013","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.cyto.2016.07.015_b0225","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1136\/annrheumdis-2013-205002","article-title":"IL-6 targeting compared to TNF targeting in rheumatoid arthritis: studies of olokizumab, sarilumab and sirukumab","volume":"73","author":"Tanaka","year":"2014","journal-title":"Emilio Martin, MolaAnn. Rheum. Dis."},{"key":"10.1016\/j.cyto.2016.07.015_b0230","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1146\/annurev.immunol.16.1.293","article-title":"Jaks and STATs: biological implications","volume":"16","author":"Leonard","year":"1998","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.cyto.2016.07.015_b0235","doi-asserted-by":"crossref","first-page":"4234","DOI":"10.4049\/jimmunol.1003668","article-title":"Modulation of innate and adaptive immune responses by tofacitinib (CP-690,550)","volume":"186","author":"Ghoreschi","year":"2011","journal-title":"J. Immunol."},{"key":"10.1016\/j.cyto.2016.07.015_b0240","doi-asserted-by":"crossref","first-page":"ii111","DOI":"10.1136\/annrheumdis-2012-202576","article-title":"Janus kinase inhibitors in autoimmune diseases","volume":"72","author":"O\u2019Shea","year":"2013","journal-title":"Arian Laurence1 Ann. Rheum. Dis."},{"key":"10.1016\/j.cyto.2016.07.015_b0245","doi-asserted-by":"crossref","first-page":"1790","DOI":"10.1002\/art.34329","article-title":"The JAK inhibitor tofacitinib regulates synovitis through inhibition of interferon-gamma and interleukin-17 production by human CD4+ T cells","volume":"64","author":"Maeshima","year":"2012","journal-title":"Arthritis Rheum."},{"issue":"6","key":"10.1016\/j.cyto.2016.07.015_b0250","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1056\/NEJMoa1109071","article-title":"Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis","volume":"367","author":"Fleischmann","year":"2012","journal-title":"N Engl. J. Med."},{"issue":"3","key":"10.1016\/j.cyto.2016.07.015_b0255","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1002\/art.37816","article-title":"Tofacitinib (CP-690,550) in patients with rheumatoid arthritis receiving methotrexate: twelve-month data from a twenty-four-month phase III randomized radiographic study","volume":"65","author":"van der Heijde","year":"2013","journal-title":"Arthritis Rheum."},{"issue":"7","key":"10.1016\/j.cyto.2016.07.015_b0260","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1002\/art.24567","article-title":"The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: results of a double-blind, placebo-controlled phase IIa trial of three dosage levels of CP-690,550 versus placebo","volume":"60","author":"Kremer","year":"2009","journal-title":"Arthritis Rheum."},{"issue":"8","key":"10.1016\/j.cyto.2016.07.015_b0265","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1002\/acr.20494","article-title":"Phase II study of tofacitinib (CP-690,550) combined with methotrexate in patients with rheumatoid arthritis and an inadequate response to methotrexate","volume":"63","author":"Tanaka","year":"2011","journal-title":"Arthritis Care Res. (Hoboken)"},{"issue":"3","key":"10.1016\/j.cyto.2016.07.015_b0270","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1002\/art.33383","article-title":"Phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) or adalimumab monotherapy versus placebo in patients with active rheumatoid arthritis with an inadequate response to disease-modifying antirheumatic drugs","volume":"64","author":"Fleischmann","year":"2012","journal-title":"Arthritis Rheum."},{"issue":"3","key":"10.1016\/j.cyto.2016.07.015_b0275","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1097\/BOR.0b013e32835190ef","article-title":"Novel small-molecular therapeutics for rheumatoid arthritis","volume":"24","author":"Fleischmann","year":"2012","journal-title":"Curr. Opin. Rheumatol."},{"issue":"6","key":"10.1016\/j.cyto.2016.07.015_b0280","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1056\/NEJMoa1112072","article-title":"Tofacitinib or adalimumab versus placebo in rheumatoid arthritis","volume":"367","author":"Van Vollenhoven","year":"2012","journal-title":"N Engl. J. Med."},{"issue":"Suppl 3","key":"10.1016\/j.cyto.2016.07.015_b0285","doi-asserted-by":"crossref","first-page":"S310","DOI":"10.1111\/j.1872-034X.2007.00249.x","article-title":"Roles of the novel interleukin-12-associated cytokine, interleukin-23, in the regulation of T-cell-mediated immunity","volume":"37","author":"Matsui","year":"2007","journal-title":"Hepatol. Res."},{"key":"10.1016\/j.cyto.2016.07.015_b0290","doi-asserted-by":"crossref","first-page":"539683","DOI":"10.1155\/2012\/539683","article-title":"The Th17\/IL-23 axis and natural immunity in psoriatic arthritis","volume":"2012","author":"Maeda","year":"2012","journal-title":"Int. J. Rheumatol."},{"key":"10.1016\/j.cyto.2016.07.015_b0295","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1016\/S0140-6736(13)60594-2","article-title":"Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1-year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT I trial","volume":"382","author":"McInnes","year":"2013","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.cyto.2016.07.015_b0300","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1136\/annrheumdis-2013-204741","volume":"73","author":"Kavanaugh","year":"2014","journal-title":"Ann. Rheum. Dis."},{"issue":"5","key":"10.1016\/j.cyto.2016.07.015_b0305","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1136\/annrheumdis-2013-204248","article-title":"Ustekinumab for the treatment of patients with active ankylosing spondylitis: results of a 28-week, prospective, open-label, proof-of-concept study (TOPAS)","volume":"73","author":"Poddubnyy","year":"2014","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.cyto.2016.07.015_b0310","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1136\/annrheumdis-2013-205056","article-title":"Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor","volume":"73","author":"Kavanaugh","year":"2014","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.cyto.2016.07.015_b0315","doi-asserted-by":"crossref","unstructured":"C.H. Smith, A.V. Anstey, J.N.W.N. Barker, A.D. Burden, R.J.G. Chalmers, D.A. Chandler, A.Y. Finlay, C.E.M. Griffiths, K. Jackson, N.J. McHugh, K.E. McKenna, N.J. Reynolds, A.D. Ormerod. British Association of Dermatologists\u2019 guidelines for biologic interventions for psoriasis, 2009.","DOI":"10.1111\/j.1365-2133.2009.09505.x"},{"key":"10.1016\/j.cyto.2016.07.015_b0320","article-title":"Impact of biologic therapy on functional status in patients with rheumatoid arthritis: a meta-analysis","volume":"2013","author":"Callhoff","year":"2013","journal-title":"Rheumatology"},{"issue":"10","key":"10.1016\/j.cyto.2016.07.015_b0325","first-page":"S362","article-title":"A randomized, double-blind, placebo-controlled, multiple-dose study to evaluate the safety, tolerability, and efficacy of brodalumab (AMG 827) in subjects with rheumatoid arthritis and an inadequate response to methotrexate","volume":"64","author":"Pavelka","year":"2012","journal-title":"Arthritis Rheum."},{"issue":"9906","key":"10.1016\/j.cyto.2016.07.015_b0330","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1016\/S0140-6736(13)61134-4","article-title":"Anti-interleukin-17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis: a randomised, double-blind, placebo-controlled trial","volume":"382","author":"Baeten","year":"2013","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.cyto.2016.07.015_b0335","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1002\/art.38617","article-title":"Phase 2 randomized study of subcutaneous ixekizumab, an Anti-IL-17 monoclonal antibody, in biologic-na\u00efve or TNF-IR patients with rheumatoid arthritis","volume":"66","author":"Genovese","year":"2014","journal-title":"Arthritis Rheumatol."},{"key":"10.1016\/j.cyto.2016.07.015_b0340","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.4049\/jimmunol.167.2.1004","article-title":"IL-1\u2013independent role of IL-17 in synovial inflammation and joint destruction during collagen-induced arthritis","volume":"167","author":"Lubberts","year":"2001","journal-title":"J. Immunol."},{"key":"10.1016\/j.cyto.2016.07.015_b0345","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1186\/ar294","article-title":"IL-17 derived from juxta-articular bone and synovium contributes to joint degradation in rheumatoid arthritis","volume":"3","author":"Chabaud","year":"2001","journal-title":"Arthritis Res."},{"issue":"7","key":"10.1016\/j.cyto.2016.07.015_b0350","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1038\/nm.3260","article-title":"How cytokine networks fuel inflammation: Toward a cytokine-based disease taxonomy","volume":"19","author":"Schett","year":"2013","journal-title":"Nat. Med."},{"key":"10.1016\/j.cyto.2016.07.015_b0355","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1007\/s11010-011-1036-6","article-title":"IL-17 receptor and its functional significance in psoriatic arthritis","volume":"359","author":"Raychaudhuri","year":"2012","journal-title":"Mol. Cell Biochem."},{"key":"10.1016\/j.cyto.2016.07.015_b0360","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1002\/art.33396","article-title":"Interleukin-17-positive mast cells contribute to synovial inflammation in spondylarthritis","volume":"64","author":"Noordenbos","year":"2012","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.cyto.2016.07.015_b0365","doi-asserted-by":"crossref","unstructured":"M. Genovese, M. Greenwald, C.S. Cho, A. Berman, L. Jin et al., A phase 2 study of multiple subcutaneous doses of LY2439821, an anti-IL17 monoclonal antibody, in patient with rheumatoid arthritis in tow populations: na\u00efve to biologic therapy or inadequate responders to tumour necrosis factor alpha inhibitors, EULAR Abstract OP0021 (2012).","DOI":"10.1136\/annrheumdis-2012-eular.1704"},{"key":"10.1016\/j.cyto.2016.07.015_b0370","doi-asserted-by":"crossref","first-page":"R129","DOI":"10.1186\/ar3067","article-title":"Effects of inflammatory cytokine IL-27 on the activation of fibroblast-like synoviocytes in rheumatoid arthritis","volume":"12","author":"Wong","year":"2010","journal-title":"Arthritis Res. Ther."},{"issue":"2","key":"10.1016\/j.cyto.2016.07.015_b0375","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.cyto.2011.04.020","article-title":"IL-27-producing CD14(+) cells infiltrate inflamed joints of rheumatoid arthritis and regulate inflammation and chemotactic migration","volume":"55","author":"Tanida","year":"2011","journal-title":"Cytokine"},{"issue":"8","key":"10.1016\/j.cyto.2016.07.015_b0380","doi-asserted-by":"crossref","first-page":"2289","DOI":"10.1002\/art.30324","article-title":"Local expression of interleukin-27 ameliorates collagen-induced arthritis","volume":"63","author":"Pickens","year":"2011","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.cyto.2016.07.015_b0385","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1136\/ard.2007.083360","article-title":"Interleukin 27 attenuates collagen-induced arthritis","volume":"67","author":"Niedbala","year":"2008","journal-title":"Ann. Rheum. Dis."},{"issue":"9","key":"10.1016\/j.cyto.2016.07.015_b0390","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1038\/ni1376","article-title":"Interleukin 27 negatively regulates the development of interleukin 17-producing T helper cells during chronic inflammation of the central nervous system","volume":"7","author":"Stumhofer","year":"2006","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.cyto.2016.07.015_b0395","doi-asserted-by":"crossref","unstructured":"Gareth W. Jones, Michele Bombardieri, Claire J. Greenhill, Louise McLeod, Alessandra Nerviani, Vidalba Rocher-Ros, Anna Cardus, Anwen S. Williams, Costantino Pitzalis, Brendan J. Jenkins, Simon A. Jones, Interleukin-27 inhibits ectopic lymphoid-like structure development in early inflammatory arthritis. JEM, vol. 212 no. 11, pp. 1793\u20131802.","DOI":"10.1084\/jem.20132307"}],"container-title":["Cytokine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043466616301843?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043466616301843?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,18]],"date-time":"2024-06-18T17:41:46Z","timestamp":1718732506000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043466616301843"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,10]]},"references-count":79,"alternative-id":["S1043466616301843"],"URL":"https:\/\/doi.org\/10.1016\/j.cyto.2016.07.015","relation":{},"ISSN":["1043-4666"],"issn-type":[{"value":"1043-4666","type":"print"}],"subject":[],"published":{"date-parts":[[2016,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Anti cytokine therapy in chronic inflammatory arthritis","name":"articletitle","label":"Article Title"},{"value":"Cytokine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cyto.2016.07.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}